Mefuparib hydrochloride
A PARP inhibitor.
General information
Mefuparib (hydrochloride) is a poly-ADP-ribose polymerase inhibitor. It was shown to bind SARS-CoV-2 Nucleocapsid protein in vitro. It inhibited SARS-CoV-2 in cell culture. The EC50 of either mefuparib or remdesivir in their mixture was observed to be decreased, which was suggested to be linked to mefuparib’s capability to decrease the local density of SARS-CoV-2 Nucleocapside-RNA-nsp12 condensates (as a phase separation modulator), and thus make it more accessible to other antivirals (Zhao et al., 2021).
Mefuparib hydrochloride on PubChem
Synonyms
CVL218; CVL-218
CNCC1=CC=C(C=C1)C2=CC3=CC(=CC(=C3O2)C(=O)N)F.Cl
Supporting references
| Link | Tested on | Impact factor | Notes | Publication date |
|---|---|---|---|---|
|
Understanding the phase separation characteristics of nucleocapsid protein provides a new therapeutic opportunity against SARS-CoV-2
Nucleocapsid protein nsp12 Biophysical assay Small molecule In vitro Mechanism |
in vitro biophysical assay; Vero E6 cells; SARS-CoV-2 strain BetaCoV/JS03/human/2020 | 10.16 | The compound inhibited SARS-CoV-2 in Vero E6 cells with an EC50 of 3.46 μM. The EC50 of either mefuparib or remdesivir in their mixture was observed to be decreased. |
Mar/26/2021 |
AI-suggested references
| Link | Publication date |
|---|---|
|
An integrative drug repositioning framework discovered a potential therapeutic agent targeting COVID-19
|
Apr/24/2021 |
